Zymeworks (ZYME) Reiterated at Market Outperform by Citizens on FDA Approval for Zani
Tweet Send to a Friend
Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $32.00 price target on Zymeworks (NASDAQ: ZYME).The analyst commented, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
